ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical effect, CT image changes and side-effects of percutaneous microwave coagulation therapy for lung cancer.</p><p><b>METHODS</b>CT-guided percutaneous puncture was performed using a needle mono-pole microwave antenna with 65W, 2 450 MHz microwave delivered in 60 seconds to 20 peripheral lung cancer patients, including 8 suffering from primary lung cancer and 12 metastatic lung cancer (totally 28 lesions).</p><p><b>RESULTS</b>Sixteen patients were alive after having been followed-up for 3 approximately 24 months. All patients showed nodules decreased in size. Diminution of over 50% was observed in 13 nodules and 3, completely disappeared. The overall response rate was 57.1%. Ellipsoid shadow 3.5 cm x 2.5 cm across was observed by CT in lesions immediately after coagulation. Gasification within the coagulated area was observed in a week with a high density in the peripheral region. Consolidation was observed in 3 months and the lesion disappeared 1 year later. Complete tumor necrosis was proved by biopsy. No side-effects or complications were observed.</p><p><b>CONCLUSION</b>Percutaneous microwave coagulation therapy is a new safe treatment for lung cancer, giving marked effect but minimum trauma.</p>
Subject(s)
Humans , Follow-Up Studies , Lung Neoplasms , Diagnostic Imaging , Pathology , Therapeutics , Microwaves , Therapeutic Uses , Survival , Time Factors , Tomography, X-Ray Computed , Methods , Treatment OutcomeABSTRACT
<p><b>BACKGROUND</b>To evaluate the efficacy and toxicity of the FUDR-based regimen in the treatment of advanced non-small cell lung cancer.</p><p><b>METHODS</b>Fifty patients in group A received the L/FUDR-EP regimen, while 42 patients in group B were given the L/FEP regimen. The response and toxicity were evaluated after three courses of treatment.</p><p><b>RESULTS</b>The therapeutic response of group A and group B were 40.0% and 38.1% respectively (P > 0.05). The toxicities such as marrow inhibition, gastrointestinal symptoms, alopecia and local phlebitis were remarkably lower in group A than those of group B (P < 0.01).</p><p><b>CONCLUSIONS</b>The FUDR based regimen is effective to the advanced NSCLC, and its toxicity is lower than 5-FU.</p>